Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy

Sun, Wenjie; Li, Guichao; Wan, Juefeng; Zhu, Ji; Shen, Weina; Zhang, Zhen

doi:10.18632/oncotarget.10875

Cited by 37 publications

(30 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Examples of successful biomarker integration include tissue expression of three proteins (c-MYC, PCNA, and TIMP1) combined with MRIdetected extramural vascular invasion [63] and the modified Glasgow prognostic score (mGPS; combination of CRP and albumin) [129]. CTCs also may be promising biomarkers as the performance of CTCs in predicting nCRT response was superior to CEA in the same sample sets [118,120]. …”

Section: Discussionmentioning

confidence: 99%

“…While the baseline CTC counts of 64 responders were significantly higher than those of 51 non-responders (44.50 ± 11.94 vs. 37.67 ± 15.45, p = 0.012); responders had significantly lower CTC counts after nCRT than non-responders (3.61 ± 2.90 vs. 12.08 ± 7.40, p < 0.001). ROC curve analysis yielded AUC of 0.860 for ∆%CTC in discriminating responders from non-responders [120]. CEA was not significantly associated with response to nCRT in these two studies.…”

Section: Biomarkers In Bloodmentioning

confidence: 99%

See 1 more Smart Citation

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer

Dayde

Tanaka

Jain

et al. 2017

IJMS

145

152

View full text Add to dashboard Cite

Abstract:The standard of care in locally advanced rectal cancer is neoadjuvant chemoradiation (nCRT) followed by radical surgery. Response to nCRT varies among patients and pathological complete response is associated with better outcome. However, there is a lack of effective methods to select rectal cancer patients who would or would not have a benefit from nCRT. The utility of clinicopathological and radiological features are limited due to lack of adequate sensitivity and specificity. Molecular biomarkers have the potential to predict response to nCRT at an early time point, but none have currently reached the clinic. Integration of diverse types of biomarkers including clinicopathological and imaging features, identification of mechanistic link to tumor biology, and rigorous validation using samples which represent disease heterogeneity, will allow to develop a sensitive and cost-effective molecular biomarker panel for precision medicine in rectal cancer. Here, we aim to review the recent advance in tissue-and blood-based molecular biomarker research and illustrate their potential in predicting nCRT response in rectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Biomarkers In Bloodmentioning

confidence: 99%

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer

Dayde

Tanaka

Jain

et al. 2017

IJMS

145

152

View full text Add to dashboard Cite

show abstract

“…Примеры успешной интеграции биомаркеров включают в себя тканевую экспрессию трех белков c-MYC, PCNA и TIMP1 в сочетании с экстрамуральной сосудистой инвазией, выявленной на МРТ [37]. Циркулирующие опухолевые клетки также могут быть многообещающими биомаркерами, поскольку их эффективность в прогнозировании ответа на терапию была выше, чем у РЭА [38].…”

Section: заключениеunclassified

Modern Radiotherapy Regimens and Biomarkers of Radioresistant Rectal Tumor Cells

et al. 2020

View full text Add to dashboard Cite

Цель исследования-обобщение имеющихся данных о различных современных схемах (протоколах) лучевой терапии и их эффективности, а также известных в настоящее время маркерах радиорезистентности клеток. Материал и методы. Поиск соответствующих источников производился в системах PubMed и cochrane Library, анализировались публикации с 1984 по 2019 г., 60 из которых были использованы для написания данного обзора. Результаты. Рак прямой кишки является одной из наиболее распространенных форм злокачественных новообразований, и за последнее десятилетие отмечен рост заболеваемости в экономически развитых странах всего мира. В России рак прямой кишки занимает одну из ведущих позиций и в настоящее время по числу диагностированных случаев и числу умерших пациентов уступает лишь таким заболеваниям, как рак легкого, рак желудка и рак молочной железы. Основным эффективным методом лечения рака прямой кишки, признанным как во всем мире, так и в России, остается выполнение предоперационной лучевой терапии с последующим хирургическим вмешательством. Однако на практике имеются случаи отсутствия реакции у пациентов на предоперационную лучевую терапию, что связано с радиорезистентностью опухолевых клеток. В настоящее время разработаны различные схемы лучевой терапии, отличающиеся по частоте возникновения местных рецидивов, общей выживаемости и качеству жизни больных. Также известны и маркеры радиорезистентности клеток-генетические (изменение экспрессии генов и микро-РНК, мутации) и протеомные (изменение экспрессии белков), которые могут не только нести прогностическую ценность, но также использоваться в качестве мишеней при терапии. Заключение. Таким образом, основная проблема, в которой заключается низкий ответ опухолей прямой кишки на различные схемы лучевой терапии,радиорезистентность опухолевых клеток. И хотя ряд молекулярных биомаркеров был предложен в качестве предикторов ответа на лучевую терапию, на данный момент ни один из них не вошел в клиническую практику. Для создания эффективной панели молекулярных биомаркеров и улучшения персонифицированной помощи при раке прямой кишки требуются дальнейшие исследования.

show abstract

“…Notably, the numbers of cells in circulation appear to be rare even in patients with known active disease, currently making it necessary to examine large specimens or use pheresis. Nevertheless, there is prognostic benefit to some existing assays, and FDA and Centers for Medicare and Medicaid approvals have been obtained for some tests allowing them to be employed in national studies (42)(43)(44)(45)(46)(47)(48). Finally, new technologies that can more accurately identify and detect tumor cells in the circulation are being developed.…”

Section: Use Of Circulating Tumor Dna (Liquid Biopsy) Biomarkers Anmentioning

confidence: 99%

Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017

Okunieff

Casey-Sawicki

Lockney

et al. 2018

Clinical Cancer Research

View full text Add to dashboard Cite

The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology-specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: (i) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? (ii) How can combined modality therapy be used to enhance systemic and local response? (iii) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? (iv) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And (v) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. .

show abstract

Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy

Cited by 37 publications

References 42 publications

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer

Modern Radiotherapy Regimens and Biomarkers of Radioresistant Rectal Tumor Cells

Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017

Contact Info

Product

Resources

About